Menu

CRISPR Gene Editing Deletes, Shuffles More Genes than Intended

The DNA-cutting enzyme used in the technique is not as precisely targeted as scientists had thought, and investors take notice.

Jul 16, 2018
Ashley Yeager

CRISPR gene editing can create large numbers of unwanted DNA changes that may go undetected, researchers report today (July 16) in Nature Biotechnology. The findings suggest that some potential treatments using the gene-editing tool may not yet be safe to test in humans.

“Anyone thinking of using this technology for gene therapy” should proceed with caution, and “check for possible harmful effects,” study coauthor Allan Bradley, a geneticist at the Wellcome Sanger Institute, tells Reuters

The data show that CRISPR’s DNA-cutting enzyme can delete or rearrange large numbers of genes beyond what it is designed to edit. The findings add to previous studies that have shown that CRISPR and other gene-editing systems can cause off-target effects and even possibly increase the risk that some edited cells could become cancerous when certain genes that should be active are not functioning properly.

See “CRISPR Efficiency Tied to Cancer-Causing Process

The changes to DNA have been “seriously underestimated,” Bradley tells STAT News. “This should be a wake-up call.”

According to STAT, the value of three publicly traded CRISPR companies dipped by more than $300 million within 20 minutes of the study’s release. Those working at the companies seem less concerned than investors. “We’re not Pollyannaish about this,” geneticist Tom Barnes, chief innovation officer at Intellia Therapeutics, tells STAT. Researchers there are using CRISPR in liver cells and “have not seen any [cancer-causing] transformation of these cells, even with all the edits we’ve introduced,” he says.

The findings add “more safety challenges to CRISPR-based gene therapies but it doesn’t compromise its use,” Gaetan Burgio, a geneticist at the Australian National University who was not involved the study, tells New Scientist.

James Haber, a molecular biologist at Brandeis University, agrees. The findings shouldn’t stop researchers from using CRISPR, he tells Nature. “It means that when people use it, they need to do a more thorough analysis” of mutations.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.